Microglial activation (neuroinflammation) is often cited as a pathogenic factor in the development of neurodegenerative diseases. However, there are significant caveats associated with the idea that inflammation directly causes either a-synuclein pathology or neurofibrillary degeneration (NFD). We have performed immunohistochemical studies on microglial cells in five cases of dementia with Lewy bodies (DLB), median age 87, and nine cases of non-demented (ND) controls, median age 74, using tissue samples from the temporal lobe and the superior frontal gyrus. Three different antibodies known to label microglia and macrophages were employed: iba1, anti-CD68, and anti-ferritin. All DLB cases showed both a-synuclein pathology (Lewy bodies and neurites) and NFD ranging from Braak stage II to IV. In contrast, all controls were devoid of a-synuclein pathology but did show NFD ranging from Braak stage I to III.
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Using iba1 labeling, our current results show a notable absence of activated microglia in all cases with the exception of two controls that showed small focal areas of microglial activation and macrophage formation. Both iba1 and ferritin antibodies revealed a mixture of ramified and dystrophic microglial cells throughout the regions examined, and there were no measurable differences in the prevalence of dystrophic microglial cells between DLB and controls. Double-labeling for a-synuclein and iba1-positive microglia showed that cortical Lewy bodies were surrounded by both ramified and dystrophic microglial cells. We found an increase in CD68 expression in DLB cases relative to controls. Since microglial dystrophy has been linked to NFD and since it did not appear to be worse in DLB cases over controls, our findings support the idea that the additional Lewy body pathology in DLB is not the result of intensified microglial dystrophy. CD68 is likely associated with lipofuscin deposits in microglial cells which may be increased in DLB cases because of impaired proteostasis. Overall, we conclude that neurodegenerative changes in DLB are unlikely to result directly from activated microglia but rather from dysfunctional ones.
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Introduction
Although microglial activation, which nowadays is often referred to by the neologism neuroinflammation, has long been implicated in the development of neurodegeneration in Alzheimer's (AD) and Parkinson's disease (PD), there remain a number of substantial caveats regarding a proposed causal link between CNS inflammation and neurodegeneration (Graeber, 2014; Streit, 2010) . A common assumption has been that activated microglia are cells out of control (Gao and Hong, 2008) , i.e. they represent neurotoxic immune effector cells that are damaging neurons. Such uncontrolled microglial neurotoxicity has only been shown using in vitro models and its perceived significance for neurodegenerative diseases is extrapolated from these models. It is unclear what kinds of events in humans could trigger an out-of-control chronic neuroinflammatory reaction so severe that it can end up destroying the brain and why it went unnoticed for decades by neuropathologists; prior to 1994, neurodegenerative diseases were never considered to have an inflammatory etiology (Akiyama, 1994; Streit et al., 2004a) . Inflammatory reactions typically develop in response to various types of injury, infection, neoplastic or autoimmune processes and there is no evidence of such triggering events occurring in either AD, PD, or dementia with Lewy bodies (DLB). It is also unclear why in some individuals neuroinflammation would cause primarily neurofibrillary degeneration (NFD) characteristic of AD, while in others it produces alpha-synuclein pathology typical of PD, and in yet another group,
